-
Featured
Innovations in ALS Clinical Trials
Merit Cudkowicz, MD, MSc, chief of Neurology at Massachusetts General Hospital, discusses innovations in ALS clinical trials since she started in the field in 1994.
-
Featured
Advancements in the Treatment of Neurodegenerative Disease
In this video, Ghazaleh Sadri-Vakili, PhD, director of the NeuroEpigenetics Laboratory and the MassGeneral Institute of Neurodegenerative Disease, discusses her genetic research, specifically concerning neurodegenerative diseases like ALS and X-linked dystonia parkinsonism.
-
Featured
Identifying New Potential Therapeutic Targets for ALS FTD
Transcripts of repeat expansions in the C90RF72 gene undergo a repeat-associated non-AUG (RAN) translation pathway that generates multiple aberrant proteins. Researchers at Mass General Hospital identified new potential therapeutic targets for ALS FTD.
-
Retinal Imaging Detects Biomarkers of Familial Alzheimer's Disease Years Before Symptoms
Mass General researchers were part of the first study to demonstrate the ability of optical coherence tomography to detect retinal biomarkers in carriers of the most common gene causing familial Alzheimer's disease.
-
Sodium Phenylbutyrate–Taurursodiol Slows Functional Decline in Patients with ALS
Treatment with co-formulated, fixed-dose sodium phenylbutyrate–taurursodiol had a modest effect in slowing the decline in total score on the Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised, a measure of function in daily activities.
-
Tofersen for ALS Clears Phase 1/2 Trial, Now in Phase 3
Tofersen, an investigational therapy for amyotrophic lateral sclerosis caused by SOD1 mutations, was safe and generally well tolerated over 12 weeks and lowered SOD1 protein levels in cerebrospinal fluid.
ALS contributors
-
Clotilde Lagier-Torurenne, MD, PhD
Assistant Professor of Neurology, Harvard Medical School, Assistant in Neuroscience, Massachusetts General Hospital
Recent Article
Researchers Identify a New Therapeutic Target for TDP-43-mediated Neurodegenerative Diseases -
Ghazaleh Sadri-Vakili, MS, PhD
Assistant in Neuroscience, Massachusetts General Hospital, Assistant Professor of Neurology, Harvard Medical School
Recent Article
Cromolyn Sodium Provides Neuroprotection in Animal Model of ALS -
James D. Berry, MD, MPH
Co-director, Multidisciplinary Amyotrophic Lateral Sclerosis (ALS) Clinic
Recent Article
Infusions of Regulatory T Cells Slowed ALS Progression in First-in-Humans Trial -
Merit Ester Cudkowicz, MD, MSc
Chief, Neurology Service, Director of the Sean M. Healey & AMG Center for ALS at Mass General, Director of Neurological Clinical Research Institute and the Jilieane Dorn Professor of Neurology, Harvard Medical School
Recent Article
Sodium Phenylbutyrate–Taurursodiol Slows Functional Decline in Patients with ALS -
Nazem Atassi, MD
Associate Director, Neurological Clinical Research Institute (NCRI), Mass General Hospital, Associate Professor of Neurology, Harvard Medical School
Recent Article
High-Dose Tamoxifen "Wins" Selection Trial in ALS